Table 2 Detailed analysis of patients needing a second surgery
Patient nr. | Corticosteroid therapy prior to first surgery | Type of first surgery | Histopathologic result | Corticosteroid therapy after first surgery | Type of second surgery | Histopathological result |
|---|---|---|---|---|---|---|
Patient 1 | Ongoing preoperative dexamethasone therapy over 26 days, maximal dose per day 12 mg, cumulative dose 236 mg | Stereotactic biopsy | Diffuse inflammation without evidence of lymphoma cells | Reduction of corticosteroid therapy, but no discontinuation. Patient was on 1 mg dexamethasone per day at time of second surgery | Stereotactic biopsy, 6 months after first surgery | Diffuse large B-cell lymphoma |
Patient 2 | No preoperative corticosteroid therapy | Stereotactic biopsy | Brain parenchyma without evidence of tumor | Contradictorily information in documentation whether corticosteroid therapy was tapered in between surgeries | Resection, 1 month after first surgery | Diffuse large B-cell lymphoma |
Patient 3 | Preoperative dexamethasone therapy for 3 days with a total dose of 52 mg and a max. daily dose of 24 mg. Corticosteroid therapy was paused 7 days prior to surgery | Stereotactic biopsy | T-cell mediated CD3 and CD8 positive inflammation with few perivascular and intra-parenchymatous lytic B-cells; unspecific result | Postoperative corticosteroid therapy was reconvened and paused again 7 days prior to second surgery | Open biopsy 18 days after first surgery | Diffuse large B-cell lymphoma |
Patient 4 | No preoperative corticosteroid therapy | Stereotactic biopsy | Unspecific inflammation with infiltration of B- and T-cells | No data on corticosteroid therapy prior to second surgery available | Stereotactic biopsy 2 months after first surgery | Diffuse large B-cell lymphoma |